CN103442704A - 用于治疗帕金森病的胱胺类似物 - Google Patents

用于治疗帕金森病的胱胺类似物 Download PDF

Info

Publication number
CN103442704A
CN103442704A CN2012800099995A CN201280009999A CN103442704A CN 103442704 A CN103442704 A CN 103442704A CN 2012800099995 A CN2012800099995 A CN 2012800099995A CN 201280009999 A CN201280009999 A CN 201280009999A CN 103442704 A CN103442704 A CN 103442704A
Authority
CN
China
Prior art keywords
cystamine
analog
disease
pharmaceutical salts
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012800099995A
Other languages
English (en)
Chinese (zh)
Inventor
弗兰切斯卡·奇凯蒂
克劳德·鲁亚尔
弗雷德里克·卡隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNIVERSITE LAVEL
Original Assignee
UNIVERSITE LAVEL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNIVERSITE LAVEL filed Critical UNIVERSITE LAVEL
Publication of CN103442704A publication Critical patent/CN103442704A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2012800099995A 2011-02-23 2012-02-23 用于治疗帕金森病的胱胺类似物 Pending CN103442704A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161445577P 2011-02-23 2011-02-23
CA2,732,440 2011-02-23
CA2732440A CA2732440C (en) 2011-02-23 2011-02-23 Cystamine analogues for the treatment of parkinson`s disease
US61/445,577 2011-02-23
PCT/CA2012/050106 WO2012113079A1 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
CN103442704A true CN103442704A (zh) 2013-12-11

Family

ID=46717621

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012800099995A Pending CN103442704A (zh) 2011-02-23 2012-02-23 用于治疗帕金森病的胱胺类似物

Country Status (11)

Country Link
US (1) US20140073694A1 (enExample)
EP (1) EP2678009B1 (enExample)
JP (1) JP6000985B2 (enExample)
KR (1) KR20140115239A (enExample)
CN (1) CN103442704A (enExample)
AU (1) AU2012220314B2 (enExample)
BR (1) BR112013021616A2 (enExample)
CA (1) CA2732440C (enExample)
MX (1) MX350195B (enExample)
RU (1) RU2630583C2 (enExample)
WO (1) WO2012113079A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613642A (zh) * 2019-03-26 2021-11-05 加利福尼亚大学董事会 取代的氨基-硫醇和氨基-二硫化物化合物及其用途
CN119909064A (zh) * 2025-04-07 2025-05-02 北京大学深圳研究生院 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用
CN120437102A (zh) * 2025-07-09 2025-08-08 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096629A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Métodos para analizar composiciones de cisteamina
TW201618760A (zh) * 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
RU2766579C2 (ru) 2015-07-02 2022-03-15 ХОРАЙЗОН ОРФАН ЭлЭлСи Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение
US10764961B2 (en) 2016-03-30 2020-09-01 Guangdong Oppo Mobile Telecommunications Corp., Ltd. Relay transmission method and device
US20220265583A1 (en) * 2019-07-30 2022-08-25 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211624A1 (en) * 2003-02-02 2006-09-21 Goverment of the US, as Represented by Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies
RU2255775C1 (ru) * 2003-12-25 2005-07-10 Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук Способ лечения болезни паркинсона
CA2640531C (en) * 2006-01-27 2017-01-03 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
WO2008143876A2 (en) * 2007-05-14 2008-11-27 The Trustees Of Columia University In The City Of New York Agents and assays for modulating neurodegeneration
CN102065687A (zh) * 2008-06-13 2011-05-18 泰华制药工业有限公司 雷沙吉兰用于改善帕金森氏症

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ME′LANIE BOUSQUET等: ""Cystamine metabolism and brain transport proterties: clinical implications for neurodegenerative disease"", 《JOURNAL OF NEUROCHEMISTRY》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613642A (zh) * 2019-03-26 2021-11-05 加利福尼亚大学董事会 取代的氨基-硫醇和氨基-二硫化物化合物及其用途
CN113613642B (zh) * 2019-03-26 2024-08-06 加利福尼亚大学董事会 取代的氨基-硫醇和氨基-二硫化物化合物及其用途
US12391643B2 (en) 2019-03-26 2025-08-19 The Regents Of The University Of California Substituted amino-thiol and amino-disulfide compounds, and uses thereof
CN119909064A (zh) * 2025-04-07 2025-05-02 北京大学深圳研究生院 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用
CN120437102A (zh) * 2025-07-09 2025-08-08 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用
CN120437102B (zh) * 2025-07-09 2025-09-16 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用

Also Published As

Publication number Publication date
KR20140115239A (ko) 2014-09-30
AU2012220314B2 (en) 2017-04-06
US20140073694A1 (en) 2014-03-13
AU2012220314A1 (en) 2013-08-22
BR112013021616A2 (pt) 2020-09-29
EP2678009B1 (en) 2017-11-01
CA2732440A1 (en) 2012-08-23
CA2732440C (en) 2017-10-31
JP2014508758A (ja) 2014-04-10
JP6000985B2 (ja) 2016-10-05
RU2013137645A (ru) 2015-02-20
RU2630583C2 (ru) 2017-09-11
WO2012113079A1 (en) 2012-08-30
EP2678009A1 (en) 2014-01-01
MX350195B (es) 2017-08-30
MX2013009608A (es) 2013-09-16
EP2678009A4 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
AU2012220314B2 (en) Cystamine analogues for the treatment of Parkinson&#39;s disease
Salamon et al. Neuroprotection in Parkinson’s disease: facts and hopes
Ossola et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GNDF in astroglia
Chung et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation
Moon et al. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson’s disease by blocking microglial activation
Edison Astroglial activation: Current concepts and future directions
Onaolapo et al. Peripheral and central glutamate dyshomeostasis in neurodegenerative disorders
JP2013543482A (ja) Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置
Yu et al. Glutamate affects the CYP1B1-and CYP2U1-mediated hydroxylation of arachidonic acid metabolism via astrocytic mGlu5 receptor
Wang et al. Phytic acid attenuates upregulation of GSK-3β and disturbance of synaptic vesicle recycling in MPTP-induced Parkinson's disease models
Pena Organotypic cultures as tool to test long-term effects of chemicals on the nervous system
GB2571978A (en) Uses, compositions and methods
Hranilovic et al. The effects of the perinatal treatment with 5-hydroxytryptophan or tranylcypromine on the peripheral and central serotonin homeostasis in adult rats
C Brett et al. Current therapeutic advances in patients and experimental models of Huntington's disease
Wang et al. Role and mechanism of molecular hydrogen in the treatment of Parkinson’s diseases
EP4554629A1 (en) Methods and formulations for gene therapy, and for combining gene therapy with ditpa treatment, of allan-herndon-dudley syndrome
Lavrova et al. Role of Oxidative Stress in the Etiology of Parkinson’s Disease: Advanced Therapeutic Products
Billet et al. Influence of glial cells in the dopamine releasing effect resulting from the stimulation of striatal δ-opioid receptors
Tan et al. FNDC5/irisin mediates hallmark brain alterations and cognitive impairment in acute intestinal injury/disease
Fernandes Impact of open channel blockers on the surface dynamics and organization of NMDA receptors
Conley et al. Effect of the β3 adrenoceptor agonist CL 316243 on hypothalamic 5-HT synthesis and suppression of REM sleep in the rat
Carbone Ih loss of function as a pathogenic mechanism underlying the selective vulnerability of nigral dopamine neurons in Parkinson’s disease
Mullins BT2 as a novel therapeutic compound for Alzheimer’s disease
AU2007203426B8 (en) Methods for treating neuropsychiatric disorders with NMDA receptor antagonists
Gelowitz Anti-apoptotic actions of (-) Deprenyl in the CNS: pharmacological, histological and behavioural evidence

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20131211